NCT05122026: Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 252 planned
- Started
- 17 Jan 2024
- Primary completion
- 24 Oct 2025
- Arms
- Arm 1: One month of daily isoniazid and rifapentine (4 weeks), Arm 2: Three months of once-weekly isoniazid and rifapentine (12 weeks)
- Results
- None posted
- 16 Nov 2021: Trial registered
- 17 Jan 2024: Trial started